Back to GTF
Cytomedix Announces Multiple Presentations at the Symposium on Advanced Wound Care Fall 2011

GAITHERSBURG, Md., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that five poster presentations highlighting the clinical merits of the Company's AutoloGel™ System in wound management will be presented at the Symposium on Advanced Wound Care (SAWC) Fall 2011 to be held at the Rio Suite Hotel & Casino in Las Vegas from Oct 13-15, 2011.

The AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel, is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.

The following posters highlighting Cytomedix's PRP technology will be presented at SAWC Fall 2011.

  • Positive Wound Healing Progress Using Platelet Rich Plasma (PRP) Gel in Patients With Low Albumin and Hemoglobin Presented by Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services at Cytomedix, Inc. Poster Number CR-008
     
  • Platelet Rich Plasma as an Adjunct to Fistula and Pseudostoma Management Presented by Denise Fuston, LPN, Tucson, AZ, Janice Wilson, RN, BSN, CWOCN, Asheville Specialty Hospital, Wound Care Coordinator, and Karl Branch, RN, Asheville Specialty Hospital, Wound Care, Asheville, NC. Poster Number CS-013
     
  • Using Platelet Rich Plasma Gel (PRP Gel) for Rapid Size Reduction in Pressure Ulcers Presented by Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services and Laurie M. Rappl, PT, DPT, CSW, Clinical Development Liaison at Cytomedix, Inc. Poster Number CR-007
     
  • Calculating Saved Costs When Using Platelet Rich Plasma Gel in Place of NPWT in 17 Complex Wound Patients Presented by Janice Wilson, RN, BSN, CWOCN, Asheville Specialty Hospital, Wound Care Coordinator, and Karl Branch, RN, Asheville Specialty Hospital, Wound Care, Asheville, NC. Poster Number CR-024
     
  • Response of Wounds of SCI Patients to Autologous Platelet Rich Plasma Gel Laurie M. Rappl, PT, DPT, CSW, Clinical Development Liaison at Cytomedix, Inc. Poster Number CS-040

"The bolus of data presented at this year's SAWC Fall 2011 underscores the clinical efficacy of AutoloGel in a variety of wound indications and highlights its economic advantage before an audience of leading wound care clinicians. The ongoing presentation of positive data in support of the use of the AutoloGel System in wound management continues to be the foundation of our clinical and scientific sales and marketing efforts," commented Martin P. Rosendale, Chief Executive Officer of Cytomedix.

About Cytomedix, Inc.

Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Additional information regarding Cytomedix is available at www.cytomedix.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the likelihood of obtaining a positive reimbursement determination on the submission, the likelihood and the extent of beneficial effect of such determination on CMS costs and care, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.

CONTACT: Cytomedix, Inc.
         David Jorden, Executive Board Member
         Martin Rosendale, CEO
         Andrew Maslan, CFO
         (240) 499-2680
         
         LHA
         Anne Marie Fields
         (afields@lhai.com)
         (212) 838-3777
         
         Bruce Voss
         (bvoss@lhai.com)
         (310) 691-7100
Back to GTF
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki